A Phase 1a/1b Study of Safety, Tolerability, and Pharmacokinetics of CB4211 in Healthy Non-obese Subjects and Subjects With Nonalcoholic Fatty Liver Disease
Phase of Trial: Phase I
Latest Information Update: 05 Nov 2019
Price : $35 *
At a glance
- Drugs CB 4211 (Primary)
- Indications Non-alcoholic steatohepatitis; Obesity
- Focus Adverse reactions; Biomarker; First in man; Pharmacodynamics
- Sponsors CohBar
- 05 Nov 2019 According to an CohBar media release, the results from both stages of the study are anticipated in mid-2020.
- 05 Nov 2019 Results published in the CohBar Media Release.
- 05 Nov 2019 According to an CohBar media release, the company announced the completion of the Phase 1a stage of this study and the initiation of recruitment for the Phase 1b stage.